Literature DB >> 24053696

New synthesis and tritium labeling of a selective ligand for studying high-affinity γ-hydroxybutyrate (GHB) binding sites.

Stine B Vogensen1, Aleš Marek, Tina Bay, Petrine Wellendorph, Jan Kehler, Christoffer Bundgaard, Bente Frølund, Martin H F Pedersen, Rasmus P Clausen.   

Abstract

3-Hydroxycyclopent-1-enecarboxylic acid (HOCPCA, 1) is a potent ligand for the high-affinity GHB binding sites in the CNS. An improved synthesis of 1 together with a very efficient synthesis of [(3)H]-1 is described. The radiosynthesis employs in situ generated lithium trimethoxyborotritide. Screening of 1 against different CNS targets establishes a high selectivity, and we demonstrate in vivo brain penetration. In vitro characterization of [(3)H]-1 binding shows high specificity to the high-affinity GHB binding sites.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24053696      PMCID: PMC3888956          DOI: 10.1021/jm4011719

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential?

Authors:  R Bernasconi; P Mathivet; S Bischoff; C Marescaux
Journal:  Trends Pharmacol Sci       Date:  1999-04       Impact factor: 14.819

2.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

3.  Binding characteristics of the gamma-hydroxybutyric acid receptor antagonist [(3)H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene) ethanoic acid in the rat brain.

Authors:  A K Mehta; N M Muschaweck; D Y Maeda; A Coop; M K Ticku
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

Review 4.  Gamma-hydroxybutyrate--a drug of abuse.

Authors:  K R Drasbek; J Christensen; K Jensen
Journal:  Acta Neurol Scand       Date:  2006-09       Impact factor: 3.209

5.  Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam.

Authors:  Wouter Koek; Lawrence P Carter; R J Lamb; Weibin Chen; Huifang Wu; Andrew Coop; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2005-03-17       Impact factor: 4.030

6.  A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties.

Authors:  M Maitre; V Hechler; P Vayer; S Gobaille; C D Cash; M Schmitt; J J Bourguignon
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

7.  The distribution of gamma-hydroxybutyrate-induced Fos expression in rat brain: comparison with baclofen.

Authors:  P S van Nieuwenhuijzen; I S McGregor; G E Hunt
Journal:  Neuroscience       Date:  2008-10-17       Impact factor: 3.590

8.  Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice.

Authors:  Klemens Kaupmann; John F Cryan; Petrine Wellendorph; Cedric Mombereau; Gilles Sansig; Klaus Klebs; Markus Schmutz; Wolfgang Froestl; Herman van der Putten; Johannes Mosbacher; Hans Bräuner-Osborne; Peter Waldmeier; Bernhard Bettler
Journal:  Eur J Neurosci       Date:  2003-11       Impact factor: 3.386

Review 9.  Behavioral analyses of GHB: receptor mechanisms.

Authors:  Lawrence P Carter; Wouter Koek; Charles P France
Journal:  Pharmacol Ther       Date:  2008-10-29       Impact factor: 12.310

10.  A mild, catalytic, and highly selective method for the oxidation of alpha,beta-enones to 1,4-enediones.

Authors:  Jin-Quan Yu; E J Corey
Journal:  J Am Chem Soc       Date:  2003-03-19       Impact factor: 15.419

View more
  4 in total

Review 1.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 2.  Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzyme-replacement therapeutic strategies.

Authors:  Kara R Vogel; Garrett R Ainslie; Dana C Walters; Alice McConnell; Sameer C Dhamne; Alexander Rotenberg; Jean-Baptiste Roullet; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2018-02-19       Impact factor: 4.982

3.  Management of Gamma-Butyrolactone Dependence with Assisted Self-Administration of GBL.

Authors:  Rafael Meyer; Josef Jenewein; Soenke Boettger
Journal:  Case Rep Neurol Med       Date:  2014-06-26

4.  GHB analogs confer neuroprotection through specific interaction with the CaMKIIα hub domain.

Authors:  Ulrike Leurs; Anders B Klein; Ethan D McSpadden; Nane Griem-Krey; Sara M Ø Solbak; Josh Houlton; Inge S Villumsen; Stine B Vogensen; Louise Hamborg; Stine J Gauger; Line B Palmelund; Anne Sofie G Larsen; Mohamed A Shehata; Christian D Kelstrup; Jesper V Olsen; Anders Bach; Robert O Burnie; D Steven Kerr; Emma K Gowing; Selina M W Teurlings; Chris C Chi; Christine L Gee; Bente Frølund; Birgitte R Kornum; Geeske M van Woerden; Rasmus P Clausen; John Kuriyan; Andrew N Clarkson; Petrine Wellendorph
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-03       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.